Publications by authors named "Ronald Marcus"

Claim this Profile
X
Xanomeline and Trospium Chloride for the Treatment of Agitation Associated With Schizophrenia: PANSS-Excited Component Results From 3 Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials.
Paul P Yeung, Alan Breier, Haiyuan Zhu, Inder Kaul, Ronald N Marcus

J Clin Psychiatry· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the 5-Week, Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials.
Inder Kaul, Amy Claxton, Sharon Sawchak, Colin Sauder, Stephen K Brannan, Ronald Marcus

J Clin Psychiatry· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale for Adjunctive Treatment Targeting Multiple Mechanisms in Schizophrenia.
Bruce J Kinon, Stefan Leucht, Carol Tamminga, Alan Breier, Ronald Marcus

J Clin Psychiatry· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comorbidities and behavioral issues.
Dragana Bugarski-Kirola, Ronald N Marcus

Eur Neuropsychopharmacol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behavior.
Jermaine D Jones, Shanna Babalonis, Ronald Marcus, Bradley Vince, Debra Kelsh

Addict Biol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A proposed anti-maladaptive aggression agent classification: improving our approach to treating impulsive aggression.
Adelaide S Robb, Stefan Schwabe, Gianpiera Ceresoli-Borroni, Azmi Nasser, Chungping Yu, Ronald Marcus

Postgrad Med· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.
J Craig Nelson, Zia Rahman, Kimberly K Laubmeier, James M Eudicone, Robert D McQuade, Ronald N Marcus

CNS Spectr· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
Anita H Clayton, Ross A Baker, John J Sheehan, Zachary J Cain, Robert A Forbes, Ronald Marcus

BMC Res Notes· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial.
Ronald Marcus, Peter J Goadsby, David Dodick, David Stock, George Manos

Cephalalgia· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder.
Robert L Findling, Raymond Mankoski, Karen Timko, Katherine Lears, Theresa McCartney, Ronald N Marcus

J Clin Psychiatry· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change.
Raymond Mankoski, Gwen Stockton, George Manos, Sabrina Marler, Robert McQuade, Ronald Marcus

J Child Adolesc Psychopharmacol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical significance of treatment effects with aripiprazole versus placebo in a study of manic or mixed episodes associated with pediatric bipolar I disorder.
Eric Youngstrom, Joan Zhao, Raymond Mankoski, Robert A Forbes, Ronald M Marcus

J Child Adolesc Psychopharmacol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years old):results from a pooled analysis of 2 studies.
Adelaide S Robb, Candace Andersson, Elizabeth E Bellocchio, George Manos, Carlos Rojas-Fernandez, Ronald Marcus

Prim Care Companion CNS Disord· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aripiprazole in bipolar depression: a pooled, post-hoc analysis by severity of core depressive symptoms.
Michael E Thase, Charles L Bowden, Michael Nashat, James M Eudicone, Ronald Marcus

Int J Psychiatry Clin Pract· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy.
James Craig Nelson, Michael E Thase, Elizabeth E Bellocchio, Linda M Rollin, James M Eudicone, Ronald N Marcus

Int Clin Psychopharmacol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of aripiprazole 2 to 15 mg/d on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post hoc analysis of two controlled trials.
James W Varni, Benjamin L Handen, Patricia K Corey-Lisle, Zhenchao Guo, George Manos, Ronald N Marcus

Clin Ther· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 40-week double-blind aripiprazole versus lithium follow-up of a 12-week acute phase study (total 52 weeks) in bipolar I disorder.
Rif S El-Mallakh, Ronald Marcus, Christine Baudelet, Robert McQuade, William H Carson

J Affect Disord· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392).
Berit X Carlson, Terence A Ketter, Wei Sun, Karen Timko, Robert D McQuade, Ronald Marcus

Bipolar Disord· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study.
Ronald N Marcus, Randall Owen, George Manos, Raymond Mankoski, Lisa Kamen

J Clin Psychiatry· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder.
Robert M Berman, Michael E Thase, Madhukar H Trivedi, James A Hazel, Sabrina Vogel Marler, Ronald N Marcus

Neuropsychiatr Dis Treat· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: results from a 52-week, open-label study.
Ronald N Marcus, Randall Owen, George Manos, Raymond Mankoski, Lisa Kamen

J Child Adolesc Psychopharmacol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study.
Ronald Marcus, Arif Khan, Linda Rollin, Beth Morris, Karen Timko

Bipolar Disord· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aripiprazole adjunctive to antidepressant therapy.
Ronald M Marcus, Raymond Sanchez, Marianne Frost, Robert D McQuade

Am J Psychiatry· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007).
Rif S El Mallakh, Eduard Vieta, Linda Rollin, Ronald Marcus, William H Carson

Eur Neuropsychopharmacol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder.
Michael G Aman, William Kasper, George Manos, Suja Mathew, Ronald Marcus

J Child Adolesc Psychopharmacol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis